Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-02-07 Purchase | 2024-02-09 5:51 pm | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 100,000 | $1.35 | $135,000 | 103,334 (Indirect Direct) | View |
2023-03-17 Sale | 2023-03-21 4:47 pm | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 10,000 | $29.05 | $290,500 | 45,841 (Indirect Direct) | View |
2021-11-15 Sale | 2021-11-17 4:38 pm | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 50,000 | $2.18 | $109,000 | 3,334 (Indirect) | View |
2021-09-15 Purchase | 2021-09-16 9:30 pm | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 6,000 | $17 | $102,000 | 89,998 (Direct) | View |
2020-02-14 Purchase | 2020-02-14 8:58 pm | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 10,000 | $13.75 | $137,500 | 30,000 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-06-27 Option Award | 2024-06-28 4:07 pm | N/A 2034-06-27 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 60,000 | $0 | 60,000 (Direct) | View |
2024-06-17 Option Award | 2024-06-20 4:44 pm | N/A 2034-06-16 | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 10,520 | $0 | 10,520 (Direct) | View |
2024-02-27 Disposition | 2024-02-28 5:34 pm | 2021-05-26 2031-04-26 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 30,000 | $0 | 8,823 (Direct) | View |
2024-02-28 Option Award | 2024-02-28 5:34 pm | N/A 2031-04-26 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 8,823 | $0 | 8,823 (Direct) | View |
2023-10-25 Option Award | 2023-10-27 4:13 pm | 2023-10-25 2030-10-25 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 91,541 | $0.125 | 274,624 (Direct) | View |
2023-10-25 Option Award | 2023-10-27 4:13 pm | N/A N/A | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 183,083 | $0.7568 | 274,624 (Direct) | View |
2023-08-09 Disposition | 2023-08-09 4:33 pm | N/A 2031-09-14 | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 96,328 | $0 | 0 (Direct) | View |
2023-08-02 Gift | 2023-08-03 7:37 pm | N/A N/A | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 2,420 | $0 | 40,921 (Indirect) | View |
2023-07-20 Option Award | 2023-07-21 4:11 pm | N/A 2033-07-20 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 20,000 | $0 | 20,000 (Direct) | View |
2023-07-18 Gift | 2023-07-19 4:53 pm | N/A N/A | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 2,200 | $0 | 43,341 (Indirect) | View |
2023-07-11 Gift | 2023-07-13 5:12 pm | N/A N/A | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 300 | $0 | 45,541 (Indirect) | View |
2023-06-09 Option Award | 2023-06-13 5:17 pm | N/A 2033-06-08 | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 40,000 | $0 | 40,000 (Direct) | View |
2023-05-01 Gift | 2023-05-02 5:49 pm | N/A N/A | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 6,923 | $0 | 45,841 (Direct) | View |
2022-10-24 Gift | 2023-03-21 4:47 pm | N/A N/A | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 30,719 | $0 | 45,841 (Direct) | View |
2022-06-23 Option Award | 2022-06-27 4:13 pm | N/A 2032-06-23 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 15,000 | $0 | 15,000 (Direct) | View |
2022-06-10 Option Award | 2022-06-14 4:22 pm | N/A 2032-06-09 | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 40,000 | $0 | 40,000 (Direct) | View |
2022-06-07 Option Award | 2022-06-08 4:53 pm | N/A 2032-06-06 | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 21,250 | $0 | 21,250 (Direct) | View |
2021-12-30 Ownership | 2022-02-11 5:33 pm | N/A N/A | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 3,000 | $0 | 55,841 (Direct) | View |
2021-09-14 Option Award | 2021-09-16 9:30 pm | N/A 2031-09-14 | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 34,157 | $0 | 89,998 (Direct) | View |
Ownership | 2021-09-14 7:34 pm | N/A N/A | DICE Therapeutics Inc. | DICE | Scopa James Paul Director | 0 | $0 | 69,000 (Direct) | View |
2021-05-12 Option Award | 2021-05-14 8:03 pm | N/A 2031-05-11 | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 40,000 | $0 | 40,000 (Direct) | View |
2021-04-26 Option Award | 2021-04-27 4:42 pm | N/A 2031-04-26 | Aligos Therapeutics Inc. | ALGS | Scopa James Paul Director | 30,000 | $0 | 30,000 (Direct) | View |
2020-06-23 Option Award | 2020-06-25 5:47 pm | N/A 2030-06-22 | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 30,000 | $0 | 30,000 (Direct) | View |
2020-05-04 Exercise | 2020-05-05 6:44 pm | N/A N/A | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 23,334 | $6.48 | 100,000 (Indirect) | View |
2020-05-04 Exercise | 2020-05-05 6:44 pm | N/A 2029-04-30 | Adverum Biotechnologies Inc. | ADVM | Scopa James Paul Director | 23,334 | $0 | 100,000 (Direct) | View |